Trials / Unknown
UnknownNCT01178697
Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)
Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Shahid Beheshti University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevasizumab | Intravitreal, 1.25 mg, 3 times, one month apart. |
| DRUG | Triamcinolone Acetonide | Intravitreal, 2 mg, 2 times, two months apart. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-09-01
- Completion
- 2010-12-01
- First posted
- 2010-08-10
- Last updated
- 2010-08-10
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT01178697. Inclusion in this directory is not an endorsement.